{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T07:57:47Z","timestamp":1791446267361,"version":"4.3.3"},"reference-count":18,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T00:00:00Z","timestamp":1635897600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.esmoop.2021.100317","type":"journal-article","created":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T23:03:21Z","timestamp":1637795001000},"page":"100317","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["How we identify and treat neuromuscular toxicity induced by immune checkpoint inhibitors"],"prefix":"10.1016","volume":"6","author":[{"given":"B.","family":"Jordan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Benesova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C.","family":"Hassel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Wick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 2","key":"10.1016\/j.esmoop.2021.100317_bib1","first-page":"S74","article-title":"Immune checkpoint inhibitors-induced neuromuscular toxicity: from pathogenesis to treatment","volume":"24","author":"Psimaras","year":"2019","journal-title":"J\u00a0Peripher Nerv Syst"},{"key":"10.1016\/j.esmoop.2021.100317_bib2","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2021.100317_bib3","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/14740338.2020.1738382","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"19","author":"Haugh","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.esmoop.2021.100317_bib4","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s40425-019-0617-x","article-title":"Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study","volume":"7","author":"Johnson","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.esmoop.2021.100317_bib5","doi-asserted-by":"crossref","first-page":"fcaa181","DOI":"10.1093\/braincomms\/fcaa181","article-title":"Immune checkpoint inhibitor-associated myopathy: a clinicoseropathologically distinct myopathy","volume":"2","author":"Shelly","year":"2020","journal-title":"Brain Commun"},{"key":"10.1016\/j.esmoop.2021.100317_bib6","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/annonc\/mdx757","article-title":"European Society for Medical Oncology (ESMO) position paper on supportive and palliative care","volume":"29","author":"Jordan","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2021.100317_bib7","doi-asserted-by":"crossref","first-page":"102586","DOI":"10.1016\/j.autrev.2020.102586","article-title":"Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities","volume":"19","author":"Allenbach","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.esmoop.2021.100317_bib8","doi-asserted-by":"crossref","first-page":"e985","DOI":"10.1212\/WNL.0000000000006124","article-title":"Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer","volume":"91","author":"Touat","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.esmoop.2021.100317_bib9","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2021.100317_bib10","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100317_bib11","doi-asserted-by":"crossref","first-page":"e000529","DOI":"10.1136\/esmoopen-2019-000529","article-title":"How I treat cancer: treatment of rheumatological side effects of immunotherapy","volume":"4","author":"Benesova","year":"2019","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2021.100317_bib12","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/annrheumdis-2020-217139","article-title":"EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors","volume":"80","author":"Kostine","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.esmoop.2021.100317_bib13","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.esmoop.2021.100317_bib14","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","article-title":"Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan","volume":"89","author":"Suzuki","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.esmoop.2021.100317_bib15","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11910-018-0878-7","article-title":"neuromuscular complications of programmed cell death-1 (PD-1) inhibitors","volume":"18","author":"Kao","year":"2018","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.esmoop.2021.100317_bib16","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418799864","article-title":"Neurological complications of immune checkpoint inhibitors: what happens when you 'take the brakes off' the immune system","volume":"11","author":"Dalakas","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.esmoop.2021.100317_bib17","doi-asserted-by":"crossref","first-page":"e1093","DOI":"10.1212\/WNL.0000000000008091","article-title":"Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies","volume":"93","author":"Dubey","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.esmoop.2021.100317_bib18","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.annonc.2020.07.003","article-title":"Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up","volume":"31","author":"Jordan","year":"2020","journal-title":"Ann Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921002799?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921002799?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:25:53Z","timestamp":1761855953000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702921002799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S2059702921002799"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100317","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How we identify and treat neuromuscular toxicity induced by immune checkpoint inhibitors","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100317","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100317"}}